Clinical Trial Update: To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children [Phase 2, Phase 3]

View source ↗

Summary

This study evaluated the immunogenicity and safety of GC1107 administered intramuscularly in healthy children in Phase 2/3; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• GC1107

Snippet

Sponsor: Green Cross Corporation | Conditions: Bacterial Infections | Phase 2, Phase 3 | Status: COMPLETED